{'fraction_non_alphanumeric': 0.044, 'fraction_numerical': 0.04533333333333334, 'mean_word_length': 5.258333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The significance of somatostatin for decreasing peri- and postoperative complications in Whipple operation].

During the period from 1987-1990 152 patients underwent a Whipple procedure at the Department of General Surgery of Münster University Hospital. 27 operations were performed for chronic pancreatitis (17.8%), 52 for pancreatic (34.2%) and 73 (48.0%) for ampullary carcinoma. All patients received Somatostatin (6 mg/24 h) postoperatively for five days. These patients were compared with those of a former series who were identically operated but did not receive Somatostatin. In-hospital-mortality was reduced from 10.7% to 4.6%. Additionally the frequency of postoperative pancreatic fistulas was reduced among the nonlethal complications.